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In vitro studies have shown that hydrogen peroxide (H2O2) produced by high-concentration ascorbate and
cell culture medium iron efficiently kills cancer cells. This provided the rationale for clinical trials of
high-dose intravenous ascorbate-based treatment for cancer. A drawback in all the in vitro studies was their
failure to take into account the in vivo concentration of iron to supplement cell culture media which are
characterized by low iron content. Here we showed, using two prostate cancer cell lines (LNCaP and PC-3)
and primary astrocytes, that the anticancer/cytotoxic effects of ascorbate are completely abolished by iron at
physiological concentrations in cell culture medium and human plasma. A detailed examination of
mechanisms showed that iron at physiological concentrations promotes both production and
decomposition of H2O2. The latter is mediated by Fenton reaction and prevents H2O2 accumulation. The
hydroxyl radical, which is produced in the Fenton reaction, is buffered by extracellular proteins, and could
not affect intracellular targets like H2O2. These findings show that anticancer effects of ascorbate have been
significantly overestimated in previous in vitro studies, and that common cell culture media might be
unsuitable for redox research.
A
number of finished (phase I) and still ongoing clinical trials have examined the possible benefits of
intravenous ascorbate (Asc) therapy in cancer treatment. High pharmacological concentrations of Asc in
the blood (approximately 5–10 mM range) are achievable only by intravenous application and appear to
be safe and tolerated1–3. The key pre-clinical rationale for such trials is found in consistent results frommore than
20 in vitro studies which concluded that pharmacological Asc efficiently kills over 50 cancer cell lines, leaving
most of the examined primary (normal) cell types unaffected4,5. Furthermore, themechanisms of Asc’s anticancer
activity were described by Chen and co-workers6, and later confirmed by others7,8, showing that Asc is a pro-drug
for extracellular generation of hydrogen peroxide (H2O2) and that iron is essential for H2O2 production. In brief,
Asc reduces iron (Fe31 to Fe21), which further reacts withmolecular oxygen forming the superoxide radical anion.
Superoxide undergoes (non)enzymatic dismutation to produce H2O2. Supra-physiological concentrations of
H2O2 enter the cell and exert cytotoxic effects. Both apoptotic and necrotic pathways of cell deathwere implicated,
with necrosis more prevalent at increasing Asc doses4.
A careful inspection of all the available reports regarding the anticancer effects of Asc reveals a systematic
omission. Namely, there is not a single study of the four-component system (Asc, iron, molecular oxygen and
cancer cell lines) that has examined the effects of different concentrations of iron. All the in vitro studies in
question have been conducted using commercial cell culturemedia, usually RPMI-1640 or DMEM supplemented
with 10% (v/v) foetal calf serum (FCS). While DMEM contains only 0.25 mM ferric nitrate (Sigma-Aldrich
formulation), iron is not a regular component of RPMI-1640 but probably exists via impurities.
Concentrations of iron in FCS are not consistent and vary between manufacturers and batches [usually 2–
5 mM in 10% (v/v) FCS]. In one particular study, the concentration of iron in 10% (v/v) FCS was 4.2 6
1.1 mM9, while another group found,3 mM Fe in RPMI-1640 with 10% (v/v) FCS10. One peculiar detail is that
iron chelators have been used in some studies in order to examine the effects of sequestration of (an unknown
amount of) iron on Asc cytotoxicity5. The key drawback in all the studies is that the concentration of iron was not
altered, measured or taken into consideration whatsoever.
The fundamental problem behind the drawback lays in the fact that physiological milieus of interest (human
plasma and interstitial fluid) containmuchmore iron compared to cell culturemedia. Total concentration of iron
in plasma is in the range of 10–30 mM11, and even higher in cancer patients12,13, as well as in patients receiving
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chemotherapy14. The concentration of iron in interstitial fluid (out-
side the CNS) closely mirrors that found in the plasma11,15, whereas
iron appears to accumulate in tumour interstitial fluid16. In addition,
Ascmay provoke the release of iron from extracellular stores, such as
ferritin which could be actively produced and released by cancer
cells7. It is important to point out that although plasma and intersti-
tial fluid share very similar redox properties17, the critical in vivo
accumulation of H2O2 could take place only in interstitial fluid, as
catalase (CAT)-rich erythrocytes buffer H2O2 in the blood. The lack
of studies that address the effects of iron at (patho)physiological
concentrations is rather perplexing, particularly if we take into
account previous findings showing that iron can protect cancer cells
from H2O218.
Herein we study the anticancer/cytotoxic activity of Asc under
conditions that reflect in vivo settings: (i) in cell culture mediumwith
(supplemented) iron at concentrations that are comparable to those
in plasma and interstitial fluid; (ii) in human plasma; and (iii) using
tumour spheroid model that mimics biological properties of micro-
metastases. We use two human prostate cancer cell lines – LNCaP
(low metastatic potential, androgen-dependent) and PC-3 (high
metastatic potential, androgen-independent), as well as primary
astrocytes. Astrocytes were selected for comparison with cancer cells
because they are: (i) ontogenetically different (ectodermal origin)
compared to prostate cells (endodermal origin): (ii) acquired from
a different species; and (iii) susceptible to Asc cytotoxicity19. Bio-
chemical assays, oximetry, electron paramagnetic resonance (EPR)
spectroscopy, and immunofluorescence are employed in order to
elucidate the interactions between Asc and iron.
Results
Total concentration of iron in the cell culture medium applied to
maintain cells (RPMI-1640 1 10% FCS) was 5.6 6 1.3 mM. This is
considerably lower compared to the iron concentration in plasma
(18.4 6 5.9 mM; p , 0.001). The level of iron in the plasma of six
volunteers ranged between 12–28 mM (Supplementary Table S1).
Incubation with pharmacological Asc (5 and 10 mM) in cell culture
medium resulted in a drastic decrease (,80%) in the number of
viable LNCaP and PC-3 cells (Fig. 1a, b). The cell culture medium
was then supplemented with iron in the form of ferric ammonium
citrate (FAC), in order tomimic the level of iron in plasma/interstitial
fluid. The concentrations of supplemented iron were 5, 10, 15, and
30 mM, resulting in the total iron concentrations of approximately
10, 15, 20, and 35 mM (,5 mM already found in the medium 1
supplemented iron). The addition of iron at a concentration as low
as 5 mM (resulting in a lower physiological limit for iron level),
annihilated the cytotoxic effects of Asc. All other iron concentrations
inhibited the cytotoxic effects of Asc as well. Additional experiments
using FeCl3 were performed in order to eliminate the possibility that
the observed effects are mediated by FAC and not by iron per se.
Ferric chloride completely inhibited the cytotoxic effects of Asc (data
not shown). It should be pointed out that iron at physiological con-
centrations provided protection irrespective of metastatic potential
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Figure 1 | Effects of pharmacological ascorbate and physiological iron on the viability of cancer and primary cells according to MTT and CV assays.
(a) LNCaP and (b) PC-3 cells treated in cell culturemedium (RPMI-16401 10%FCS)with different concentrations of supplemented iron; * - statistically
significant (p , 0.05) compared to control with the same amount of supplemented iron. (c) Primary astrocytes treated with Asc (5 mM) and/or iron
(30 mM) in cell culture medium. (d) LNCaP (left) and PC-3 (right) in human plasma; Bars not sharing a common letter are significantly different
(p, 0.05). (e) LNCaP and (f) PC-3 cells treated in cell culture medium with different % (v/v) of FCS; Bars not sharing a common letter are significantly
different (p, 0.05); * - non-significant compared to control with the same% (v/v) of FCS. Statistical analysis was performed using one-way or two-way
ANOVA with post hoc Duncan test.
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of the two cell lines. A similar experiment was performed on primary
astrocytes. Fig. 1c shows that the supplementation of iron also alle-
viated the cytotoxic effects of Asc on non-cancer cells. Finally, Asc
had very little effect on cancer cell viability in human plasma
(Fig. 1d). Only a slight decrease in viability was found for LNCaP
cells exposed to 10 mM Asc. Supplementary Table S1 shows the
results of viability tests for each of 6 plasma samples. Asc (10 mM)
provoked a slight decrease of viability of LNCaP cells only in some
plasma samples. Of note, no CAT activity could be detected in the
plasma using two different assays. This is in line with previous
notions that plasma contains no (or very little) CAT20,21. Further,
we modified the level of iron in cell culture medium by increasing
the volume percent concentration of FCS, where 10% (v/v) increase
add ,5 mM to the total iron concentration. It can be observed that
cytotoxic effects of Asc were gradually alleviated with increasing FCS
percentage (Fig. 1e, f).
A set of experiments was performed in order to elucidate the
mechanisms of iron’s cytoprotective activity. Increased ascorbyl rad-
ical production (Fig. 2a) andO2 consumption (Fig. 2b) imply that the
generation of H2O2 is higher in the presence of iron at physiological
concentration compared to cell culture medium iron. Ascorbyl rad-
ical is a by-product of Asc-mediated reduction of iron (Fe31 to Fe21),
and represents a marker of H2O2 production in this system22. The
level of H2O2was estimated by the addition of CATwhich resulted in
a rapid and transient O2 production fromH2O2 breakdown (Fig. 2b).
The amount of O2 produced and the rate of O2 production were
much smaller/lower in the presence of iron at physiological concen-
tration, compared to the system with cell culture medium concen-
tration of iron. If we take into account that CAT uses two H2O2
molecules for each O2 produced (2H2O2 R 2H2O 1 O2), the
steady-state concentration of H2O2 in the presence of cell culture
medium iron is estimated to be around 25 mM. Physiological iron
reduced the level ofH2O2 to 1.5 mM.This is in contrast to the amount
of O2 that was consumed in these systems prior to CAT addition.
Further, it can be observed that CAT almost fully restored the level of
O2 in the systemwith cell culturemedium concentration of iron. This
is not true for physiological iron, implying the production of end-
product(s) other than H2O2. Ascorbyl radical is produced in the
plasma supplemented with Asc (Fig. 2c), implying that Asc is redox
active and that H2O2 is produced in this system. Ascorbyl radical
concentrations found in our experiments correspond to levels in
the plasma of cancer patients receiving Asc intravenously23. Polaro-
graphic measurements on plasma resemble data obtained on cell
culture medium with physiological concentration of Fe. Only traces
of H2O2 could be detected in plasma supplemented with Asc
(Fig. 2d). Altogether these results show that in the presence of phar-
macological Asc, physiological Fe promotes H2O2 decomposition,
thus not allowing H2O2 accumulation. In the presence of cell culture
medium concentration of iron, H2O2 accumulates because its degra-
dation is very slow or completely absent.
Fig. 3a shows that the incubation of cancer cells with Asc in cell
culture medium results in a significant decrease in the level of intra-
cellular thiol (-SH) groups, which are the main targets for H2O2-
provoked oxidation24. This is in line with previous findings8,25.
However, in the presence of iron at physiological concentration,
the Asc-mediated decrease in the level -SH groups was abolished,
i.e. iron prevented intracellular oxidation. Fenton reaction (Fe21 1
H2O2R Fe31 1 OH2 1
NOH) appears as a plausible mechanism of
removal of extracellular H2O2 in the system with physiological iron.
Asc is known to propel the Fenton reaction by maintaining iron in
Fe21 form, which is otherwise unstable under physiological pH26,27.
We applied biochemical assays in order to quantify extracellular
markers of hydroxyl radical (NOH)-mediated oxidation of proteins
and lipids. Fig. 3b shows that the level of oxidation of extracellular
proteins was about three times higher in the presence of physiological
level of iron compared to culture medium iron concentration. The
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Figure 2 | The effects of ascorbate and iron on hydrogen peroxide production in cell culturemedium and human plasma. (a) Concentration of ascorbyl
radical (marker of H2O2 production) in cell culture medium samples that were collected after incubation of LNCaP or PC-3 cells for the purposes of
viability measurements (results presented in Fig. 1); Box: Characteristic EPR signal of ascorbyl radical with spectral simulation (pale); * - statistically
significant (p , 0.05) compared to control (no Fe supplemeted). (b) The concentration of molecular oxygen and the rate of O2 consumption in cell
culture medium supplemented with Asc (5 mM) or Fe (5 mM) 1 Asc (5 mM). CAT (600 U) was added at 15 min. The change in O2 concentration
following CAT supplementation is presented as mean 6 S.D. (c) Concentration of ascorbyl radical in human plasma samples collected after the
incubation of LNCaP or PC-3 cells for the purposes of viability measurements; A low level of ascorbyl radical was found in some untreated plasma
samples; Bars not sharing a common letter are significantly different (p , 0.05). (d) The concentration of molecular oxygen and the rate of O2
consumption in plasma supplemented with Asc (5 mM). Characteristic polarographic recordings obtained on plasma samples from three healthy
volunteers (total Fe concentrations: volunteer (1) 23.0 mM; (2) 15.4 mM; (3) 24.2 mM) are presented. CAT was added at 15 min. Statistical analysis was
performed using one-way ANOVA with post hoc Duncan test.
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level of lipid peroxidation was not affected by iron supplementation
(Fig. 3c). All these experiments have been also performed using
30 mM supplemented iron with very similar results. Altogether this
implies that iron at physiological concentration and pharmacological
Asc propel the production of NOH, most of which are removed by
protein oxidation. It is important to point out that we have applied
EPR spin-trapping spectroscopy in order to directly detect the pro-
duction of NOH. However, in line with our previous experience, spin-
trapping in Asc-rich systems is unfeasible because Asc reduces
spin-adducts. Finally we tested the ability of pharmacological Asc
and physiological Fe to protect cells from exogenous H2O2 (Fig. 3d,
e). It can be observed that Asc in the presence of cell culture medium
iron, as well as iron supplemented without Asc were incapable of
protecting cancer cells. However, pharmacological Asc in combina-
tion with physiological Fe promoted degradation of H2O2 and
diminished its cytotoxic effects.
Two additional mechanisms that might be relevant for Fe-
mediated cytoprotection against Asc were examined. It has been
speculated that prolonged exposure of cancer cells to Ascmight exert
cytotoxic effects via provoking iron deficiency28,29. However, Fig. 4
shows that the total intracellular concentration of iron remains un-
affected in the presence of extracellular Asc, implying that the cyto-
protective effects of iron against Asc-provoked cell death are not
related to iron deficiency. Further, it is known that the level of hyp-
oxia inducible factor-1 (HIF-1), a transcription factor that is involved
in the regulation of different aspects of cancer cell biology, can be
affected by Asc30–32, iron33,34, and H2O235. Fig. 5 shows characteristic
micrographs, intensities and histograms of HIF-1a immunofluores-
cence. In LNCaP cells, Asc provoked an increase in HIF-1a level. In
addition, it can be observed that percentage distribution of Asc-
treated LNCaP cells was shifted towards higher florescence intens-
ities. Asc-provoked increase in HIF-1a level was diminished by iron
(Fig. 5a). PC-3 cells showed a higher constitutive level ofHIF-1a. The
level was not affected by Asc, but the combination of pharmaco-
logical Asc and physiological Fe provoked its decrease (Fig. 5b).
Fig. 6 shows the effects of Asc and Asc 1 Fe on multi-cellular
tumour spheroid culture of LNCaP. It can be observed that Asc at
both concentrations applied here exerted only weak tumour static
effects, which appear not to be affected by iron supplementation.
Discussion
This is the first study of the anticancer effects of Asc that has taken
into account physiological concentrations of iron. Schemes depicted
in Fig. 7 summarise what is known about the pro-oxidative antic-
ancer activity of Asc in the cell culture medium, and what we have
shown herein to take place in settings that resemble in vivo condi-
tions. Sub-physiological concentrations of iron in cell culture media
allow the accumulation of H2O2, which easily crosses the membrane
in order to provoke intracellular oxidative damage resulting in cell
death (Fig. 7a). On the other hand, when iron is present at the
physiological level (even at the lower physiological limit), the decom-
position of H2O2 compensates for H2O2 generation and prevents its
accumulation (Fig. 7b). The removal of H2O2 is conducted predomi-
nately via the NOH-generating Fenton reaction. Hydroxyl radical is
considered to be themost notorious reactive oxygen species due to its
high reactivity (about 109 times less stabile compared to H2O2)36.
However, for the same reason, extracellularly-produced hydroxyl
radical is incapable of reaching sensitive intracellular targets18.
Most hydroxyl radicals are buffered by extracellular proteins and
some by Asc and membrane lipids. Oxidised lipids are reduced by
Asc/tocopherol coupled antioxidative activity37. Under such settings
reactive oxygen species remain in the extracellular compartment
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leaving cancer cells generally unharmed. It should be stressed out
that presented mechanisms are not dependent on cancer cells and
types, as documented by using two lines with different metastatic
potentials and ontogenetically different non-cancer cells.
It has been shown recently that HIF-1a-signalling cascade is
essential for cancer cells’ resistance to ascorbate-provoked cytotoxi-
city31. The level of inducible subunit of HIF-1 (HIF-1a) is regulated
by hydroxylation, which is performed by HIF-1 prolyl hydroxylases
(HPH), leading to HIF-1a degradation. HPH show a complex net of
regulators that involves Asc, Fe21, and O2, which are required for
HPH activity, as well as reducing agents (such as thiols that activate
these enzymes), different glucose metabolites, and H2O234. Several
studies have shown that the supplementation of Asc to cultured
cancer cells provokes a drop in HIF-1a level32–34. However, we found
that Asc provoked an increase in HIF-1a level in LNCaP whereas it
did not exert significant effects in PC-3 cells. A plausible explanation
is in the opposing effects of Asc and H2O2 on the activity of HPH.
Namely, in contrast to Asc, H2O2 is known to inhibit HPH and to
provoke an increase in the HIF-1a level35. It is tempting to speculate
that H2O2-provoked inhibition of HPH prevailed over the activating
effects of Asc in LNCaP cells, which showed low constitutive HIF-1a
level and in relation to this a probable high HPH activity. Hydrogen
peroxide-mediated inhibition of HPH could take place either via
intracellular oxidation of Fe21 to Fe31 or via a decrease in the intra-
cellular level of thiols and Asc. In PC-3 cells, constitutive HIF-1a
level was high (as noted previously33), so inhibitory effects of H2O2
on HPH could not be exerted/observed, and/or the opposing effects
of Asc and H2O2 were balanced. Of note, high constitutive HIF-1a
levels have been observed in many highly glycolytic cancer cells, and
it appears to be related to pyruvate- and oxaloacetate-mediated
inhibition of HPH34. The setup changed in the presence of physio-
logical iron. In LNCaP, Asc-provoked increase was significantly
reduced, whereas in PC-3 the level of HIF-1a felt below baseline.
These effects aremost likely related the ability of physiological iron to
prevented Asc-provoked H2O2 accumulation. Under such settings,
HIF-1a lowering effects of supplemented Ascmost likely emerged. It
is worth mentioning that the supplementation of iron did not
increase the intracellular iron concentration, however Asc might
maintain iron in Fe21 in the intracellular compartment thus increas-
ing HPH activity. Altogether these phenomena are interesting, but
appear only to reflect redox settings in our system. In other words, a
decrease in the level of pro-survival factor in cells that were protected
from the cytotoxic effects of Asc appears not to be directly involved in
the mechanisms of protection.
Although our experimental setup took into account the total con-
centration of iron in relevant biological milieus (plasma and inter-
stitial fluid), redox activity of iron in cell culture media and in vivo is
further complicated by a number of iron-binding molecules, such as
transferrin and feritin38. The concentrations of transferrin and ferri-
tin as well as their saturation with iron in FCS are not consistent9, so
their effects on redox activity of iron in cell culture medium are hard
to estimate. Pertinent to this, it was essential to examine the effects of
Asc on cancer cells in biological fluid. The absence of anticancer
effects in human plasma implies that our setup (medium supplemen-
ted with iron) properly reflects in vivo redox milieu. In addition,
anticancer effects gradually decreased in cell culture medium with
increasing volume percent concentration of FCS, i.e. with increasing
resemblance of the applied medium with biological fluid. It can be
further argued that the redox activity of the Asc/Fe system in inter-
stitial fluid, which is the main site of Asc’s anticancer activity in vivo,
could be different compared to plasma, since these differ in composi-
tion (for example in their proteome39). However, it has been docu-
mented that interstitial fluid and plasma show similar capacities to
prevent iron-dependent oxidation17. It is noteworthy that the pro-
blems of unsuitability of common cell culture media for redox
research, which clearly emerged in this case, have been outlined also
by others and might affect the performance of a number of com-
pounds other than Asc40.
The Pauling/Cameron–Creagan/Moertel ‘‘conflict’’ about the
applicability of oral Asc in cancer treatment that went on throughout
the 1970’s and the 1980’s ended in disappointment41. As a matter of
fact, the concept of oral Asc application suffered from a major error
at the very beginning. Namely, the bioavailability of ingested Asc is
limited by the refractory response – a set of mechanisms that our
Figure 5 | The level of HIF-1a in cancer cells exposed to Asc (5 mM) and Fe (5 mM). (a) LNCaP. (b) PC-3. Micrographs showing HIF-1a
immunofluorescence and HIF-1amerged with DAPI staining of nuclei, average per-pixel intensities of HIF-1a immunofluorescence (bars not sharing a
common letter are significantly different and percentage distribution of cells according to average per-pixel intensities of fluorescence are presented (the
number of cells (%) was bracketed to 10 AU steps). Cells were stained 2 h after the treatment. Statistical analysis was performed using one-way ANOVA
with post hoc Duncan test. All statistical differences were at the 0.001 level.
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organism uses in order to maintain flexible redox poise and normal
redox signalling36. The findings of Levine and co-workers that even
mega doses of oral Asc cannot raise its level in the blood over modest
200 mM pointed out the problem42. This instigated renewed interest
in the application of Asc in cancer treatment, but this time using
intravenous administration in order to bypass limited intestinal
absorption and to reach millimolar Asc concentrations in the blood
and interstitial fluid4,5. This was followed by somewhat spectacular
results of a large number of in vitro studies which showed that cancer
cells are efficiently killed by pharmacological Asc acting as a pro-
drug for H2O2 production. Unfortunately, it appears that research of
the anticancer effects of Asc suffered from systematic errors once
again and that we are on the verge of yet another disappointment. In
addition to findings presented here, other evidence predict a grim
future for Asc-based cancer therapy. For example, Asc shows rela-
tively limited efficiency in animal tumour models43. Pertinent to this,
we employed tumour spheroid model which shows complexity that
is between in vivo tumours and monolayer cultures, and which is
known to be more resistant to anticancer agents compared to the
latter44. Only weak tumour static effects were observed implying that
Asc-based therapy might suffer frommore than one shortcoming. In
addition, completed phase I clinical trials showed no objective antic-
ancer response to treatment with pharmacological Asc1–3, and it
appears that Asc has already slipped from the group of potential
anticancer drugs to a category of chemotherapy adjuvants45,46.
Nevertheless, a number of clinical trials are underway and our find-
ings could be used in order to adjust current therapeutic approaches.
Co-application of iron chelators in order to reduce redox active iron
to a level that promotes the anticancer activity of Asc appears to be
realistic. Iron chelation has shown significant in vitro and in vivo
anticancer effects irrespective of Asc (most likely by causing iron
deficiency)47. There are still many problems with iron chelation ther-
apy, such as limited bioavailability, misdosing and toxicity38, but in
order to promote Asc’s anticancer effects, less aggressive agents, such
as disulfiram, might be sufficient48.
Methods
Cells. Human androgen-dependent and androgen-independent prostate cancer cell
lines, LNCaP and PC-3, were a kind gift fromProf. FerdinandoNicoletti (Department
of Biomedical Sciences, University of Catania, Italy). Cell lines were validated by short
tandem repeat DNA fingerprinting, and matched known American Type Culture
Collection (ATCC, Rockville, USA) fingerprints. Cells in logarithmic growth phase
were cultured in RPMI-1640 medium supplemented with 10% (v/v) FCS (PAA
Laboratories, Pasching, Austria), 2 mM L-glutamine, 0.01% sodium pyruvate and
antibiotics (culture medium) (Sigma-Aldrich, St. Louis, MO, USA), at 37uC in a
humidified atmosphere with 5%CO2. After standard trypsinisation, cells were seeded
in flat-bottomed 96-well plates (Sarstedt, Nu¨mbrecht, Germany) (7 3 103 cells/well
for LNCaP and 5 3 103 cells/well for PC-3) for viability determination, or in 6-well
plates (3 3 105/well) for other measurements. Astrocytes were isolated from mixed
glial cell cultures prepared from brains of newborn Dark Agouti rats as previously
described49. Astrocytes were grown in the above-mentioned culture medium
supplemented with 4 g/L glucose. They were purified by repetition of trypsinisation
(0.25% trypsin and 0.02% EDTA, both from Sigma-Aldrich) and re-plating. The cells
used in these experiments were obtained after the third passage. Astrocytes were
seeded at 1.5 3 105 cells/mL/well in 24-well plates.
Treatment.Cells were incubated for 2 h in RPMI-1640 with 10% FCS or in undiluted
human plasma (collected on the day of experiment), with or without L-ascorbic acid
(Sigma-Aldrich) at final concentrations of 5 or 10 mM. Two hour incubation period
mimics clinical pharmacokinetics and has been applied previously in similar in vitro
studies. Ascorbate stocks were buffered to pH 7.0 with NaOH and prepared
immediately before use. Ironwas added to cell culturemedium at final concentrations
of 0, 5, 10, 15, and 30 mM in the form of FAC (17% iron content, Serva, Heidelberg,
Germany) or FeCl3 (Sigma-Aldrich). Treatment with H2O2 (200 mM; Carlo Erba
Reagents, Milano, Italy) was performed in the absence or the presence of Asc (5 mM)
and/or FAC (5 mM). Plasma samples were obtained from six healthy volunteers
between the ages of 30 and 45 years (m/f 5 3/3), using Vacutainer tubes containing
Li-heparin as the anticoagulant per 4 mL of blood (BD, Franklin Lakes, NJ, USA) and
centrifugation (2000 g/10 min/4uC). A tourniquet was applied to the upper arm
Figure 6 | Effects of pharmacological Asc on the size of tumour
spheroids. (a) Images of LNCaP spheroids obtained at 103 and 23
magnification. (b) The effects of Asc (5 mM) and Fe (5 mM) on spheroid
growth. (c) The effects of Asc (10 mM) and Fe (5 mM)on spheroid growth.
Area of each sphere was normalized to its area at 0 h (at the start of the
treatment). a - significant compared to initial area (0 h); b - significant
compared to area at 4 h. Statistical analysis was performed using one-way
ANOVA with post hoc Duncan test.
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Figure 7 | Redox activity of Asc/Fe system. (a) In cell culture media.
(b) Under in vivo settings with physiological iron concentration. Asc
reduces Fe31 to Fe21, which react with O2 in order to produce superoxide.
The latter is dismutated to H2O2, which can affect cancer cells or be
decomposed, depending on iron concentration. The decomposition is
mediated via Fenton reaction and the oxidation of extracellular proteins
and Asc. It is important to note that in vivo iron is not free but bound to
hydroxyl, phosphate ions, small ligands or proteins (not presented). NAsc -
ascorbyl radical; CG - carbonyl groups; NO2
- - superoxide radical anion;
NOH - hydroxyl radical.
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during sampling from antecubital vein and sampling was completed within 90 s
following the tourniquet application. A special care was made in order to prevent
haemolysis or the collection of erythrocytes or buffy coat. All procedures related to the
use of human blood in this study are in conformity with the recommendation
provided in The Code of Ethics of the World Medical Association (Declaration of
Helsinki) for experiments involving humans. The protocols were approved by the
local Ethics Committee. Viability experiments were performed in triplicate for each
plasma sample. Iron was not supplemented to plasma samples.
Viability assays. Reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
2Htetrazolium bromide (MTT; Sigma-Aldrich) to formazan reflects mitochondrial
activity and viability of cultured cells, while the number of adherent, viable cells
correlates with crystal violet (CV) (Mol, Belgrade, Serbia) staining. Following 2 h
incubation period, supernatants were collected for EPR measurements, while cells
were washed with PBS and resuspended in cell culture medium for additional 24 h.
To evaluate mitochondrial respiration, MTT solution was added to cell cultures at the
final concentration of 0.5 mg/mL, incubated for 1 h, after which produced formazan
was dissolved in DMSO. In CV assay, adherent cells were first fixed with 4% PFA for
10 min and subsequently stained with 1% CV for 15 min at room temperature. The
cells were then washed, dried, and dye was dissolved in 33% acetic acid.
Mitochondria-dependent production of formazan and the intensity of absorbed CV
by adherent cells were assessed with an automated microplate reader at 570/640 nm.
Cell viability was expressed relative to control (untreated cells; same experimental
day).
Biochemical assays. Following 2 h incubation, with or without iron (5 mM) and/or
Asc (5 mM), supernatants were collected, while cells were washed 3 times with PBS,
snap frozen in liquid N2 and stored at 280uC. Frozen cells were detached with a
Teflon cell scraper, dissolved in extraction buffer and centrifuged at 30000 g for
90 min. Intracellular content of thiol groups was determined according to Ellman50.
Total concentration of intracellular iron was determined according to the method of
Rad et al.51. Protein concentration was determined by the method of Bradford52. 2,4-
Dinitrophenylhydrazine was used for determining carbonyl content in supernatants
according to Levine et al.53. The carbonyl content was calculated from the absorbance
measurement at 380 nm and an absorption coefficient of 22000 M21 cm21. The level
of malondialdehyde (MDA) wasmeasured according to procedure of Ohkawa et al.54.
The concentration of iron in the plasma and medium was determined according to
the method of Bouda55. CAT activity in plasma was determined using two previously
described methods56,57.
EPR measurements. Samples were placed in Teflon tubes with a wall thickness of
0.025 mm and an internal diameter of 0.6 mm (Zeus Industries, Raritan, NJ, USA)
and inserted into quartz capillaries. EPR spectra were recorded using aVarian E104-A
EPR spectrometer operating at X-band (9.51 GHz), and EW software (Scientific
Software Inc., Bloomington, IL, USA). EPR signal of ascorbyl radical in supernatants
was recorded using the following settings: modulation amplitude, 2 G; modulation
frequency, 100 kHz; microwave power, 20 mW. Simulation and double integration
of EPR spectra of ascorbyl radical were performed in order to determine intensities of
EPR signal of ascorbyl radical, usingWINEPR SimFonia Computer Program (Bruker
AnalytischeMesstechnik GmbH, Karlsruhe, Germany) and simulation parameter: aH
5 2.1. The concentration of ascorbyl radical was determined using calibration curve
that was prepared with 3-carboxyproxyl (Sigma-Aldrich) as a standard37. For the EPR
assay for -SH groups36, cells were trypsinized, washed twice in PBS, resuspended in
PBS at a density of 1.5 3 105 cells/100 mL, and placed on ice. Thiol-sensitive biradical
spin probe RSSR (Enzo Life Sciences International, PlymouthMeeting, PA, USA) was
dissolved in DMSO and added to a final concentration of 100 mM. EPR spectra were
recorded after 4 min incubation, using the following settings: modulation amplitude,
1 G; modulation frequency, 100 kHz; microwave power, 10 mW. The concentration
of -SH groups was determined using calibration curve that was prepared with
glutathione as a standard for intracellular thiols.
Oximetry. The O2 concentration and the rate of oxygen consumption/production
(d[O2]/dt) was determined using a Clark electrode – OX1LP Dissolved Oxygen
Package (Qubit Systems Inc, Kingston, ON, Canada) operating with Logger Pro 1
software (Vernier, Beaverton, OR,USA). Experiments were performed in RPMI-1640
1 10% (v/v) FCSwith or without the addition of Asc (5 mM) and/or FAC (5 mM). All
systems were recorded for 5 min before the addition of Asc and/or Fe, in order to
establish the stability of baseline and zero rate of O2 change (not shown).
Accumulation of H2O2 was determined by measuring O2 production induced by the
addition of CAT to the system58. Although various other assays and probes for H2O2
quantification are available, most of them are likely to be interfered by millimolar
concentrations of Asc59. CAT (600 U; Sigma-Aldrich C1345) was added at the point
when systems approached a zero rate of O2 consumption. Polarographic
measurements were also performed on plasma samples of three volunteers. CAT was
supplemented 15 min after the application of Asc (5 mM).
HIF-1a immunofluorescence and quantification.Cells were seeded in glass bottom
chambers (Lab-TekH II Chamber Slide
TM, Thermo Fisher Scientific, Waltham, MA,
USA) at 3 3 104 cells/chamber overnight. Cells were treated with Asc (5 mM) or Asc
1 Fe (5 mM) for 2 h, washed and resuspended in cell culture medium for additional
2 h at 37uC. Cells were fixed with 4% PFA at 4uC for 15 min and permeabilized in
Triton X-100 (0.25%) for 10 min, which was followed by the blocking of non-specific
staining with FCS (10%) for 30 min. Then, cells were stained withmouse anti-HIF-1-
alpha [H1alpha67] (Abcam, Cambridge, UK) (1/200) antibody overnight at 4uC, and
visualized with fluorophore-labelled secondary antibody Alexa Fluor 555 donkey
anti-mouse (Life Technologies - Invitrogen, Carlsbad, CA, USA) (1/500). Cell nuclei
were counterstained with DAPI. Images were acquired using Zeiss Axiovert
microscope (Carl Zeiss, Jena, Germany). Fluorescence measurements were
performed using Image J (NIH, USA), as described previously60. Mean per-pixel
fluorescence intensity of HIF-1a in the cross-section area of nucleus of each cell was
evaluated and presented as arbitrary units (AU). In addition, the percentage
distribution of cells showing fluorescence intensities within specific range (10 AU
steps were used, e.g. 0–10 AU, 10–20 AU, etc) was established. The whole range of
fluorescence intensities (0–255 AU) was covered. It is important to note that HIF-1a
was not specifically located in nuclei, but this area was selected because it is well
defined unlike the cross-section area of the whole cell.
Tumour spheroids. Spheroids were formed using a modified method of Ivascu and
Kubbies61. In brief, 1 3 104 LNCaP cells were suspended in 100 mL of ice-cold
medium and placed in standard polystyrene 96-well plate with a round bottom
(Sarstedt, Nu¨mbrecht, Germany; Prod. No. 82.1582.001). MatrigelH (BD Labware,
Bedford, MA, USA) was applied at 2.5% (v/v) using ice-cold pipette tip. Spheroid
formation was initiated by centrifugation of the plates at 1000 g for 10 min. The
plates were incubated under standard cell culture conditions for 2 days, after which
compact spheroid morphology was evident. The number of spheroids was 10–20 per
well. It is noteworthy that previously described procedure for formation of a single
spheroid used poly-HEMA–coated plates and a lower number of LNCaP cells per mL
(1 3 104 cells in 200 mL)61. Spheroids were further untreated or treated with Asc
(5 mM or 10 mM), Fe (5 mM), or with both Asc and Fe. Final volume per well was
200 mL. Images of spheroids were acquired immediately after, and 4 h and 24 h after
the beginning of the treatment, using Zeiss Axiovert microscope and magnifier Leica
MZ16 (LeicaMicrosystems, Heerbrugg, Switzerland). Cells were treated for 24 h. The
treatment could not be stopped, i.e. medium change was not possible, because it
would result in the movement and/or decomposition of spheroids. For each
treatment, cross-section areas of 20 spheroids with distinct round morphology
(randomly selected in three wells) were followed up andmeasured at three time points
using Image J. The area of each spheroid at 4 h and 24 h was normalized to the area at
the beginning of the treatment.
Statistics. All experiments were performed at least three times on separate
experimental days. The data are presented as mean 6 standard deviation (S.D.).
Statistical differences between the values obtained in different experimental settings
were evaluated by the means of ANOVA (two-way or one-way as appropriate) with
post hoc Duncan’s range test (p, 0.05) using STATISTICA 8.0 (StatSoft Inc, Tulsa,
OK, USA).
1. Riordan, H. D. et al. A pilot clinical study of continuous intravenous ascorbate in
terminal cancer patients. P. R. Health Sci. J. 24, 269–276 (2005).
2. Hoffer, L. J. et al. Phase I clinical trial of i.v. ascorbic acid in advancedmalignancy.
Ann. Oncol. 19, 1969–1974 (2008).
3. Stephenson, C. M., Levin, R. D., Spector, T. & Lis, C. G. Phase I clinical trial to
evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous
ascorbic acid in patients with advanced cancer. Cancer Chemother. Pharmacol.
72, 139–146 (2013).
4. Parrow, N. L., Leshin, J. A. & Levine, M. Parenteral ascorbate as a cancer
therapeutic: A reassessment based on pharmacokinetics. Antioxid. Redox Signal.
19, 2141–2156 (2013).
5. Du, J., Cullen, J. J. & Buettner, G. R. Ascorbic acid: chemistry, biology and the
treatment of cancer. Biochim. Biophys. Acta 1826, 443–457 (2012).
6. Chen, Q. et al. Ascorbate in pharmacologic concentrations selectively generates
ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc. Natl.
Acad. Sci. USA 104, 8749–8754 (2007).
7. Deubzer, B. et al. H2O2-mediated cytotoxicity of pharmacologic ascorbate
concentrations to neuroblastoma cells: potential role of lactate and ferritin. Cell.
Physiol. Biochem. 25, 767–774 (2010).
8. Olney, K. E. et al. Inhibitors of hydroperoxide metabolism enhance ascorbate-
induced cytotoxicity. Free Radic. Res. 47, 154–163 (2013).
9. Kakuta, K., Orino, K., Yamamoto, S. &Watanabe, K. High levels of ferritin and its
iron in fetal bovine serum. Comp. Biochem. Physiol. A Physiol. 118, 165–169
(1997).
10. Wesselius, L. J. et al. Iron uptake promotes hyperoxic injury to alveolar
macrophages. Am. J. Respir. Crit. Care Med. 159, 100–106 (1999).
11. Ganz, T. & Nemeth, E. Hepcidin and disorders of iron metabolism. Annu. Rev.
Med. 62, 347–360 (2011).
12. Bae, Y. J., Yeon, J. Y., Sung, C. J., Kim, H. S. & Sung, M. K. Dietary intake and
serum levels of iron in relation to oxidative stress in breast cancer patients. J. Clin.
Biochem. Nutr. 45, 355–360 (2009).
13. Panis, C. et al. Differential oxidative status and immune characterization of the
early and advanced stages of human breast cancer. Breast Cancer Res. Treat. 133,
881–888 (2012).
14. Weijl, N. I. et al. Non-protein bound iron release during chemotherapy in cancer
patients. Clin. Sci. (Lond.) 106, 475–484 (2004).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 5955 | DOI: 10.1038/srep05955 7
15. Cavill, I., Staddon, G. & Jacobs, A. Iron kinetics in the skin of patients with iron
overload. J. Invest. Dermatol. 58, 96–98 (1972).
16. Freitas, I. et al. Iron accumulation in mammary tumor suggests a tug of war
between tumor and host for the microelement. Anticancer Res. 27, 3059–3065
(2007).
17. Dabbagh, A. J. & Frei, B. Human suction blister interstitial fluid prevents metal
ion-dependent oxidation of low density lipoprotein by macrophages and in cell-
free systems. J. Clin. Invest. 96, 1958–1966 (1995).
18. Hempel, S. L., Buettner, G. R., Wessels, D. A., Galvan, G. M. & O’Malley, Y. Q.
Extracellular iron (II) can protect cells from hydrogen peroxide. Arch. Biochem.
Biophys. 330, 401–408 (1996).
19. Herst, P. M., Broadley, K. W., Harper, J. L. & McConnell, M. J. Pharmacological
concentrations of ascorbate radiosensitize glioblastoma multiforme primary cells
by increasing oxidativeDNAdamage and inhibitingG2/Marrest. Free Radic. Biol.
Med. 52, 1486–1493 (2012).
20. Halliwell, B. & Gutteridge, J. M. The antioxidants of human extracellular fluids.
Arch. Biochem. Biophys. 280, 1–8 (1990).
21. Halliwell, B. &Gutteridge, J.M. C. Free Radicals in Biology andMedicine. 145–146
(Oxford University Press, Oxford, 2007).
22. Chen, Q. et al. Pharmacologic ascorbic acid concentrations selectively kill cancer
cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc. Natl. Acad.
Sci. USA 102, 13604–13609 (2005).
23. Welsh, J. L. et al. Pharmacological ascorbate with gemcitabine for the control of
metastatic and node-positive pancreatic cancer (PACMAN): results from a phase
I clinical trial. Cancer Chemother. Pharmacol. 71, 765–775 (2013).
24. Spasojevic´, I., Jones, D. R. & Andrades, M. E. Hydrogen peroxide in adaptation.
Oxid. Med. Cell. Longev. 2012, 596019 (2012).
25. Park, S. et al. L-Ascorbic acid induces apoptosis in acutemyeloid leukemia cells via
hydrogen peroxide-mediated mechanisms. Int. J. Biochem. Cell Biol. 36,
2180–2195 (2004).
26. Riemer, J., Hoepken, H. H., Czerwinska, H., Robinson, S. R. & Dringen, R.
Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells.
Anal. Biochem. 331, 370–375 (2004).
27. Tulpule, K., Robinson, S. R., Bishop, G.M. &Dringen, R. Uptake of ferrous iron by
cultured rat astrocytes. J. Neurosci. Res. 88, 563–571 (2010).
28. Kang, J. S. et al. Sodium ascorbate (vitamin C) induces apoptosis in melanoma
cells via the down-regulation of transferrin receptor dependent iron uptake.
J. Cell. Physiol. 204, 192–197 (2005).
29. Carosio, R., Zuccari, G., Orienti, I., Mangraviti, S. & Montaldo, P. G. Sodium
ascorbate induces apoptosis in neuroblastoma cell lines by interfering with iron
uptake. Mol. Cancer 6, 55 (2007).
30. Kuiper, C., Dachs, G. U., Currie, M. J. & Vissers, M. C. Intracellular ascorbate
enhances hypoxia-inducible factor (HIF)-hydroxylase activity and preferentially
suppresses the HIF-1 transcriptional response. Free Radic. Biol. Med. 69, 308–317
(2014).
31. Sinnberg, T. et al. The ROS-induced cytotoxicity of ascorbate is attenuated by
hypoxia and HIF-1alpha in the NCI60 cancer cell lines. J. Cell Mol. Med. 18,
530–541 (2014).
32. Kawada, H. et al. High concentrations of L-ascorbic acid specifically inhibit the
growth of human leukemic cells via downregulation of HIF-1a transcription.
PLoS One 8, e62717 (2013).
33. Knowles, H. J., Raval, R. R., Harris, A. L. & Ratcliffe, P. J. Effect of ascorbate on the
activity of hypoxia-inducible factor in cancer cells. Cancer Res. 63, 1764–1768
(2003).
34. Lu, H., Dalgard, C. L., Mohyeldin, A., McFate, T., Tait, A. S. & Verma, A.
Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to
control basal HIF-1. J. Biol. Chem. 280, 41928–41939 (2005).
35. Qutub, A. A. & Popel, A. S. Reactive oxygen species regulate hypoxia-inducible
factor 1alpha differentially in cancer and ischemia.Mol. Cell Biol. 28, 5106–5019
(2008).
36. Spasojevic´, I. Free radicals and antioxidants at a glance using EPR spectroscopy.
Crit. Rev. Clin. Lab. Sci. 48, 114–142 (2011).
37. Sharma, M. K. & Buettner, G. R. Interaction of vitamin C and vitamin E during
free radical stress in plasma: an ESR study. Free Radic. Biol. Med. 14, 649–653
(1993).
38. Kell, D. B. Iron behaving badly: inappropriate iron chelation as a major
contributor to the aetiology of vascular and other progressive inflammatory and
degenerative diseases. BMC Med. Genomics 2, 2 (2009).
39.Wiig, H., Tenstad, O., Iversen, P. O., Kalluri, R. & Bjerkvig, R. Interstitial fluid: the
overlooked component of the tumor microenvironment? Fibrogenesis Tissue
Repair. 3, 12 (2010).
40. Halliwell, B. Oxidative stress in cell culture: an under-appreciated problem? FEBS
Lett. 540, 3–6 (2003).
41. Wittes, R. E. Vitamin C and cancer. N. Engl. J. Med. 312, 178–179 (1985).
42. Levine, M. et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a
recommended dietary allowance. Proc. Natl. Acad. Sci. USA 93, 3704–3709
(1996).
43. Tian, J., Peehl, D. M. & Knox, S. J. Metalloporphyrin synergizes with ascorbic acid
to inhibit cancer cell growth through fenton chemistry. Cancer Biother.
Radiopharm. 25, 439–448 (2010).
44. Zhang, X. et al. Induction of mitochondrial dysfunction as a strategy for targeting
tumour cells in metabolically compromised microenvironments. Nat. Commun.
5, 3295 (2014).
45. Cullen, J. J., Spitz, D. R. & Buettner, G. R. Comment on ‘‘Pharmacologic ascorbate
synergizes with gemcitabine in preclinical models of pancreatic cancer,’’ i.e., all we
are saying is, give C a chance. Free Radic. Biol. Med. 50, 1726–1727 (2011).
46. Wilson, M. K., Baguley, B. C., Wall, C., Jameson, M. B. & Findlay, M. P. Review of
high-dose intravenous vitamin C as an anticancer agent. Asia. Pac. J. Clin. Oncol.
10, 22–37 (2014).
47. Dixon, S. J. & Stockwell, B. R. The role of iron and reactive oxygen species in cell
death. Nat. Chem. Biol. 10, 9–17 (2014).
48. Spasojevic´, I. et al. Bioavailability and catalytic properties of copper and iron for
Fenton chemistry in human cerebrospinal fluid. Redox Rep. 15, 29–35 (2010).
49. McCarthy, K. D. & de Vellis, J. Preparation of separate astroglial and
oligodendroglial cell cultures from rat cerebral tissue. J. Cell. Biol. 85, 890–902
(1980).
50. Ellman, G. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82, 70–77 (1959).
51. Rad, A., Janic, B., Iskander, A. S. M., Soltanian-Zadeh, H. & Arbab, A.
Measurement of quantity of iron inmagnetically labeled cells: comparison among
different UV/VIS spectrometric methods. BioTechniques 43, 627–636 (2007).
52. Bradford,M.M.A rapid and sensitivemethod for the quantification ofmicrogram
quantities of protein utilizing the principles of protein-dye binding. Anal.
Biochem. 72, 248–254 (1976).
53. Levine, R. L. et al. Determination of carbonyl content in oxidatively modified
proteins. Methods Enzymol. 186, 464–478 (1990).
54. Ohkawa, H., Ohishi, N. & Yagi, K. Assay for lipid peroxides in animal tissues by
thiobarbituric acid reaction. Anal. Biochem. 95, 351–358 (1979).
55. Bouda, J. Determination of iron with bathophenanthroline without
deproteinisation. Clin. Chim. Acta. 21, 159–160 (1968).
56. Iwase, T. et al. A simple assay for measuring catalase activity: a visual approach.
Sci. Rep. 3, 3081 (2013).
57. Claiborne, A. Handbook of Methods for Oxygen Radical Research. 76–81 (CRC
Press Inc, Boca Raton, 1984).
58. Cle´ment, M. V., Ramalingam, J., Long, L. H. & Halliwell, B. The in vitro
cytotoxicity of ascorbate depends on the culture medium used to perform the
assay and involves hydrogen peroxide.Antioxid. Redox Signal. 3, 157–163 (2001).
59. Rawal, M. et al. Manganoporphyrins increase ascorbate-induced cytotoxicity by
enhancing H2O2 generation. Cancer Res. 73, 5232–5241 (2013).
60. Bajic´, A. et al. Fluctuating vs. continuous exposure to H2O2: the effects on
mitochondrialmembrane potential, intracellular calcium, andNF-kB in astroglia.
PLoS One 8, e76383 (2013).
61. Ivascu, A. & Kubbies, M. Rapid generation of single-tumor spheroids for high
throughput cell function and toxicity analysis. J. Biomol. Screen. 11, 922–932
(2006).
Acknowledgments
This work was supported by the Ministry of Science, Education and Technological
Development of the Republic of Serbia, grant numbers 173013 and 173014. We thank Jana
Blazˇevski and Filip Petkovic´ at the Department of Immunology, Institute for Biological
Research ‘‘Sinisˇa Stankovic´’’ for excellent technical assistance.
Author contributions
I.S. and D.M.I. designed the research; M.M., J.B.P., M.S., D.M.I., S.M., and I.S. performed
the experiments; I.S., J.B.P., M.M., and M.S. analysed the data. I.S., D.J., M.M., J.B.P., and
D.M.I. wrote the paper.
Additional information
Supplementary information accompanies this paper at http://www.nature.com/
scientificreports
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Mojic´, M. et al. Extracellular iron diminishes anticancer effects of
vitamin C: An in vitro study. Sci. Rep. 4, 5955; DOI:10.1038/srep05955 (2014).
This work is licensed under a Creative Commons Attribution-NonCommercial-
NoDerivs 4.0 International License. The images or other third party material in
this article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative
Commons license, users will need to obtain permission from the license holder
in order to reproduce the material. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-nd/4.0/
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 5955 | DOI: 10.1038/srep05955 8
